UNSPSC 51381509: Triflumidate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H14F3NO5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V6G94Z48FK, chemically known as carbanilic acid, m-benzoyl-n-((trifluoromethyl)sulfonyl)-, ethyl ester but generally known as triflumidate, which bears US NIH Compound Identifier 32259. European Medicines Agency schedules Triflumidate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11286MIG.

UNSPSC 51381509 Triflumidate is a Commodity code, but the recent state and local procurement activity tagged under it does not match the code's pharmaceutical scope — the only recent opportunity on record is Seminole County, Florida's IFB 60459723LAS, which solicits naloxone and drug deactivation systems, neither of which are triflumidate products. The mismatch suggests either a tagging error in the source data or a misclassification of the commodity code itself. The code shows little relevant recent activity aligned with its stated pharmaceutical product line.

Seminole County released the naloxone and drug deactivation systems IFB on June 30, 2026, with a response deadline of July 26, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The county requires E-Verify compliance, drug-free workplace certification, and standard insurance coverage; the contract carries a two-year initial term with a one-year renewal option and a three-month probationary period. Prospective vendors should verify UNSPSC coding in their own tracking systems before pursuing opportunities listed under this code, as the procurement activity observed does not align with triflumidate products or typical pharmaceutical purchasing patterns in state and local markets.